Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study investigated the efficacy and safety of Baerveldt glaucoma implants (BGI) in adults with uveitic glaucoma (UG) at the Manchester Uveitis Clinic. This was a retrospective study of 42 patients with UG who underwent BGI implantation between 2006 and 2015. Primary outcome measures were intraocular pressure (IOP) reduction and number of medications at 5-year follow-up. Three IOP success criteria were chosen: 1.IOP ≤21 mmHg and ≥20% reduction from baseline 2.IOP ≤17 mmHg and ≥20% reduction from baseline and 3.IOP ≤14 mmHg. The mean pre-operative IOP was 29.5 ± 9.5 mmHg on 3.9 antiglaucoma drops. At 5-year follow-up, IOP reduced to 14.4 ± 7.0 mmHg ( < 0.005) on 1.4 drops. The cumulative probability of failure at 5 years based on criteria 1, 2, and 3 was 24.3%, 39.6%, and 56.3%, respectively. This study demonstrated that BGI are safe and effective in refractory UG, especially in younger adults with complex uveitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2018.1517892 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: To evaluate the efficacy and safety of a Baerveldt valve implant technique without creating a scleral flap and without using a scleral patch in refractory cases of secondary glaucoma.
Methods: This is a retrospective, interventional, consecutive case series. We included 52 eyes affected by refractory glaucoma that were recruited for Baerveldt tube implant.
Preserflo™ microshunt for the treatment of refractory childhood glaucoma: A case series study.
Am J Ophthalmol Case Rep
September 2025
Department of Ophthalmology, Nagoya University Graduate School of Medicine, 65, Tsurumai, Syowa Ward, Nagoya, Aichi, 466-8560, Japan.
Purpose: We report the outcomes of five patients with pediatric glaucoma, who were treated with Preserflo™ microshunt surgery.
Methods: This prospective study included five consecutive patients who underwent Preserflo™ microshunt surgery at the Nagoya University Hospital. The main outcome measures evaluated in this study were mean intraocular pressure (IOP), number of glaucoma medications, and best corrected visual acuity (BCVA).
Neovascular Proliferation over a Cosmetic Artificial Iris Implant.
Case Rep Ophthalmol
June 2025
Ophthalmology Unit, DIMEC, Alma Mater Studiorum Università di Bologna, Bologna, Italy.
Introduction: The NewColorIris and BrightOcular implants were initially developed to address congenital iris defects. However, they found application for cosmetic purposes. Unfortunately, these implants are frequently linked to severe complications, including glaucoma, endothelial dysfunction, cataract development, and iris abnormalities.
View Article and Find Full Text PDFA single center experience of intraocular pressure control with glaucoma drainage device use in pediatric and adult patients.
Jpn J Ophthalmol
July 2025
Department of Ophthalmology, Mayo Clinic, Rochester, MN, 55905, USA.
Purpose: This retrospective cohort compared the cumulative probability of success for glaucoma drainage device (GDD) implantation in pediatric and adult patients.
Study Design: This retrospective study enrolled adult and pediatric patients who had received a GDD between January 1, 1985 and December 31, 2017.
Methods: Kaplan-Meier method was used to estimate the cumulative probability of success in the pediatric and adult patients.
Outcomes of glaucoma tube shunt implantation with vitrectomy in eyes with neovascular glaucoma.
Int Ophthalmol
June 2025
Department of Ophthalmology and Micro-Technology, Yokohama City University, 4-57 Urafune, Minami-Ku, Yokohama, 232-0024, Japan.
Purpose: To evaluate the clinical outcomes of tube shunt surgery combined with pars plana vitrectomy (PPV) in eyes with neovascular glaucoma (NVG), using either the Ahmed Glaucoma Valve (AGV) or the Baerveldt Glaucoma Implant (BGI).
Methods: This retrospective observational study included 41 eyes of 38 patients with NVG who underwent combined PPV and tube shunt surgery between 2015 and 2020. All tubes were inserted into the vitreous cavity.